Board Change

RNS Number : 5026K
Oxford Biomedica PLC
21 April 2010
 



 

For Immediate Release

21 APRIL 2010

 

OXFORD BIOMEDICA PLC

BOARD CHANGE

 

Oxford, UK - 21 April 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that Nick Woolf has informed the Board that he wishes to step down as Chief Business Officer and Executive Director. Nick has decided to leave the Company purely for personal reasons as his family is planning to move to Australia. It is anticipated that Nick will step down on 30 June 2010, although he is committed to a smooth transfer of his responsibilities and has offered to extend his departure if required.

 

Nick aims to continue his industry career in Australia. He has joined the Board of Phylogica Limited (ASX: PYC), a drug discovery company based in Perth, Western Australia, as a Non-Executive Director. Phylogica has also appointed Nick as a consultant to support its international investor relations strategy.    

 

Oxford BioMedica's Chairman, Professor Alan Kingsman, said: "Nick has been a key member of the senior management team for the past seven years and has played an instrumental role in strengthening both our business development and also our corporate communications activities. We will be sorry to see Nick leave, but we respect his decision. On behalf of the Board, I would like to thank Nick for his considerable contribution and commitment to Oxford BioMedica and we wish him every success in his new pursuits."

 

Nick Woolf commented: "It has been a difficult personal decision to leave Oxford BioMedica, particularly at a time when the Company is pursuing multiple collaborations and exploring other opportunities to build the business. Oxford BioMedica's development candidates and technology platform have tremendous potential and I have every confidence that the Company will succeed. It has been a privilege to work with such talented and dedicated colleagues and I look forward to following the Company's progress."

      

-Ends-

 

For further information, please contact:


Oxford BioMedica plc:

John Dawson, Chief Executive Officer

 

Tel: +44 (0)1865 783 000

JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson

 

Tel: +44 (0)20 7588 2828

City/Financial Enquiries:

Lisa Baderoon/ Mark Court

Buchanan Communications

 

Tel: +44 (0)20 7466 5000

US Enquiries:

Thomas Fechtner

The Trout Group LLC

 

Tel: (646) 378 2900

 

Notes to editors

 

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

MSCKKKDQPBKDDQB